Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats

•TRH and TRH-like peptides increase throughout limbic system 1h after ketamine.•This increase may be due to increased ascorbate-dependent synthesis of TRH-like peptides.•Glu-TRH increased levels of TRH-like peptides via competitive inhibition of degrading enzymes.•Anxiolytic effects of ketamine may...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Peptides (New York, N.Y. : 1980) N.Y. : 1980), 2015-07, Vol.69, p.66-76
Hauptverfasser: Pekary, A. Eugene, Sattin, Albert, Lloyd, Robert L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 76
container_issue
container_start_page 66
container_title Peptides (New York, N.Y. : 1980)
container_volume 69
creator Pekary, A. Eugene
Sattin, Albert
Lloyd, Robert L.
description •TRH and TRH-like peptides increase throughout limbic system 1h after ketamine.•This increase may be due to increased ascorbate-dependent synthesis of TRH-like peptides.•Glu-TRH increased levels of TRH-like peptides via competitive inhibition of degrading enzymes.•Anxiolytic effects of ketamine may be mediated by TRH and/or TRH-like peptides. Major depression is the largest single healthcare burden with treatments of slow onset and often limited efficacy. Ketamine, a NMDA antagonist used extensively as a pediatric and veterinary anesthetic, has recently been shown to be a rapid acting antidepressant, making it a potential lifesaver for suicidal patients. Side effects and risk of abuse limit the chronic use of ketamine. More complete understanding of the neurobiochemical mechanisms of ketamine should lead to safer alternatives. Some of the physiological and pharmacological actions of ketamine are consistent with increased synthesis and release of TRH (pGlu-His-Pro-NH2), and TRH-like peptides (pGlu-X-Pro-NH2) where “X” can be any amino acid residue. Moreover, TRH-like peptides are themselves potential therapeutic agents for the treatment of major depression, anxiety, bipolar disorder, epilepsy, Alzheimer's and Parkinson's diseases. For these reasons, male Sprague–Dawley rats were anesthetized with 162mg/kg ip ketamine and then infused intranasally with 20μl of sterile saline containing either 0 or 5mg/ml Glu-TRH. One, 2 or 4h later, the brain levels of TRH and TRH-like peptides were measured in various brain regions and peripheral tissues. At 1h in brain following ketamine only, the levels of TRH and TRH-like peptides were significantly increased in 52 instances (due to increased biosynthesis and/or decreased release) or decreased in five instances. These changes, listed by brain region in order of decreasing number of significant increases (↑) and/or decreases (↓), were: hypothalamus (9↑); piriform cortex (8↑); entorhinal cortex (7↑); nucleus accumbens (7↑); posterior cingulate (5↑); striatum (4↑); frontal cortex (2↑,3↓); amygdala (3↑); medulla oblongata (1↑,2↓); cerebellum (2↑); hippocampus (2↑); anterior cingulate (2↑). The corresponding changes in peripheral tissues were: adrenals (8↑); epididymis (4↑); testis (1↑,3↓); pancreas (1↑); prostate (1↑). We conclude that TRH and TRH-like peptides may be downstream mediators of the rapid antidepressant actions of ketamine.
doi_str_mv 10.1016/j.peptides.2015.04.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1684432795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196978115001084</els_id><sourcerecordid>1684432795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-94cdceba12e67649f7052f753134870ae6ea31f568ad7c24bafeb1a09d2b1b693</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EotvCX6h87CVhnDiOfSuqgKJWqoTK2ZrYE-FtvrCdSvx7stptr73MXJ6Zd-Zh7FJAKUCoL_tyoSUHT6msQDQlyBKgfsd2Qrd10Qhl3rMdCKMK02pxxs5T2gOAlEZ_ZGdVo3UFoHcM7yjjGCbi4-zXATMl_vjrluPkD70YwhPxUxTPa5zmZ4o8TLyLuNUDtlAMyx-KOPAcUlq3DXPPRxyIR8zpE_vQ45Do86lfsN_fvz3e3Bb3Dz9-3ny9L1ytdC6MdN5Rh6Ii1Spp-haaqm-bWtRSt4CkCGvRN0qjb10lO-ypEwjGV53olKkv2NVx7xLnv9sR2Y4hORoGnGhekxVKS1lXrWk2VB1RF-eUIvV2iWHE-M8KsAe9dm9f9NqDXgvSbnq3wctTxtqN5F_HXnxuwPURoO3T50DRJhdocuRDJJetn8NbGf8BWdWP6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1684432795</pqid></control><display><type>article</type><title>Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Pekary, A. Eugene ; Sattin, Albert ; Lloyd, Robert L.</creator><creatorcontrib>Pekary, A. Eugene ; Sattin, Albert ; Lloyd, Robert L.</creatorcontrib><description>•TRH and TRH-like peptides increase throughout limbic system 1h after ketamine.•This increase may be due to increased ascorbate-dependent synthesis of TRH-like peptides.•Glu-TRH increased levels of TRH-like peptides via competitive inhibition of degrading enzymes.•Anxiolytic effects of ketamine may be mediated by TRH and/or TRH-like peptides. Major depression is the largest single healthcare burden with treatments of slow onset and often limited efficacy. Ketamine, a NMDA antagonist used extensively as a pediatric and veterinary anesthetic, has recently been shown to be a rapid acting antidepressant, making it a potential lifesaver for suicidal patients. Side effects and risk of abuse limit the chronic use of ketamine. More complete understanding of the neurobiochemical mechanisms of ketamine should lead to safer alternatives. Some of the physiological and pharmacological actions of ketamine are consistent with increased synthesis and release of TRH (pGlu-His-Pro-NH2), and TRH-like peptides (pGlu-X-Pro-NH2) where “X” can be any amino acid residue. Moreover, TRH-like peptides are themselves potential therapeutic agents for the treatment of major depression, anxiety, bipolar disorder, epilepsy, Alzheimer's and Parkinson's diseases. For these reasons, male Sprague–Dawley rats were anesthetized with 162mg/kg ip ketamine and then infused intranasally with 20μl of sterile saline containing either 0 or 5mg/ml Glu-TRH. One, 2 or 4h later, the brain levels of TRH and TRH-like peptides were measured in various brain regions and peripheral tissues. At 1h in brain following ketamine only, the levels of TRH and TRH-like peptides were significantly increased in 52 instances (due to increased biosynthesis and/or decreased release) or decreased in five instances. These changes, listed by brain region in order of decreasing number of significant increases (↑) and/or decreases (↓), were: hypothalamus (9↑); piriform cortex (8↑); entorhinal cortex (7↑); nucleus accumbens (7↑); posterior cingulate (5↑); striatum (4↑); frontal cortex (2↑,3↓); amygdala (3↑); medulla oblongata (1↑,2↓); cerebellum (2↑); hippocampus (2↑); anterior cingulate (2↑). The corresponding changes in peripheral tissues were: adrenals (8↑); epididymis (4↑); testis (1↑,3↓); pancreas (1↑); prostate (1↑). We conclude that TRH and TRH-like peptides may be downstream mediators of the rapid antidepressant actions of ketamine.</description><identifier>ISSN: 0196-9781</identifier><identifier>EISSN: 1873-5169</identifier><identifier>DOI: 10.1016/j.peptides.2015.04.003</identifier><identifier>PMID: 25882008</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Anxiety ; Brain - drug effects ; Brain - metabolism ; Brain - physiopathology ; Depression ; Depressive Disorder, Major - drug therapy ; Depressive Disorder, Major - metabolism ; Depressive Disorder, Major - physiopathology ; Humans ; Ketamine - administration &amp; dosage ; Ketamine - metabolism ; Limbic system ; Male ; N-Methylaspartate - antagonists &amp; inhibitors ; N-Methylaspartate - metabolism ; Neuroendocrine ; Peptides - metabolism ; Rats ; Rats, Sprague-Dawley ; Suicide ; Thyrotropin-Releasing Hormone - biosynthesis ; Thyrotropin-Releasing Hormone - metabolism</subject><ispartof>Peptides (New York, N.Y. : 1980), 2015-07, Vol.69, p.66-76</ispartof><rights>2015</rights><rights>Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-94cdceba12e67649f7052f753134870ae6ea31f568ad7c24bafeb1a09d2b1b693</citedby><cites>FETCH-LOGICAL-c368t-94cdceba12e67649f7052f753134870ae6ea31f568ad7c24bafeb1a09d2b1b693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0196978115001084$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25882008$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pekary, A. Eugene</creatorcontrib><creatorcontrib>Sattin, Albert</creatorcontrib><creatorcontrib>Lloyd, Robert L.</creatorcontrib><title>Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats</title><title>Peptides (New York, N.Y. : 1980)</title><addtitle>Peptides</addtitle><description>•TRH and TRH-like peptides increase throughout limbic system 1h after ketamine.•This increase may be due to increased ascorbate-dependent synthesis of TRH-like peptides.•Glu-TRH increased levels of TRH-like peptides via competitive inhibition of degrading enzymes.•Anxiolytic effects of ketamine may be mediated by TRH and/or TRH-like peptides. Major depression is the largest single healthcare burden with treatments of slow onset and often limited efficacy. Ketamine, a NMDA antagonist used extensively as a pediatric and veterinary anesthetic, has recently been shown to be a rapid acting antidepressant, making it a potential lifesaver for suicidal patients. Side effects and risk of abuse limit the chronic use of ketamine. More complete understanding of the neurobiochemical mechanisms of ketamine should lead to safer alternatives. Some of the physiological and pharmacological actions of ketamine are consistent with increased synthesis and release of TRH (pGlu-His-Pro-NH2), and TRH-like peptides (pGlu-X-Pro-NH2) where “X” can be any amino acid residue. Moreover, TRH-like peptides are themselves potential therapeutic agents for the treatment of major depression, anxiety, bipolar disorder, epilepsy, Alzheimer's and Parkinson's diseases. For these reasons, male Sprague–Dawley rats were anesthetized with 162mg/kg ip ketamine and then infused intranasally with 20μl of sterile saline containing either 0 or 5mg/ml Glu-TRH. One, 2 or 4h later, the brain levels of TRH and TRH-like peptides were measured in various brain regions and peripheral tissues. At 1h in brain following ketamine only, the levels of TRH and TRH-like peptides were significantly increased in 52 instances (due to increased biosynthesis and/or decreased release) or decreased in five instances. These changes, listed by brain region in order of decreasing number of significant increases (↑) and/or decreases (↓), were: hypothalamus (9↑); piriform cortex (8↑); entorhinal cortex (7↑); nucleus accumbens (7↑); posterior cingulate (5↑); striatum (4↑); frontal cortex (2↑,3↓); amygdala (3↑); medulla oblongata (1↑,2↓); cerebellum (2↑); hippocampus (2↑); anterior cingulate (2↑). The corresponding changes in peripheral tissues were: adrenals (8↑); epididymis (4↑); testis (1↑,3↓); pancreas (1↑); prostate (1↑). We conclude that TRH and TRH-like peptides may be downstream mediators of the rapid antidepressant actions of ketamine.</description><subject>Animals</subject><subject>Anxiety</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Brain - physiopathology</subject><subject>Depression</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Depressive Disorder, Major - metabolism</subject><subject>Depressive Disorder, Major - physiopathology</subject><subject>Humans</subject><subject>Ketamine - administration &amp; dosage</subject><subject>Ketamine - metabolism</subject><subject>Limbic system</subject><subject>Male</subject><subject>N-Methylaspartate - antagonists &amp; inhibitors</subject><subject>N-Methylaspartate - metabolism</subject><subject>Neuroendocrine</subject><subject>Peptides - metabolism</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Suicide</subject><subject>Thyrotropin-Releasing Hormone - biosynthesis</subject><subject>Thyrotropin-Releasing Hormone - metabolism</subject><issn>0196-9781</issn><issn>1873-5169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EotvCX6h87CVhnDiOfSuqgKJWqoTK2ZrYE-FtvrCdSvx7stptr73MXJ6Zd-Zh7FJAKUCoL_tyoSUHT6msQDQlyBKgfsd2Qrd10Qhl3rMdCKMK02pxxs5T2gOAlEZ_ZGdVo3UFoHcM7yjjGCbi4-zXATMl_vjrluPkD70YwhPxUxTPa5zmZ4o8TLyLuNUDtlAMyx-KOPAcUlq3DXPPRxyIR8zpE_vQ45Do86lfsN_fvz3e3Bb3Dz9-3ny9L1ytdC6MdN5Rh6Ii1Spp-haaqm-bWtRSt4CkCGvRN0qjb10lO-ypEwjGV53olKkv2NVx7xLnv9sR2Y4hORoGnGhekxVKS1lXrWk2VB1RF-eUIvV2iWHE-M8KsAe9dm9f9NqDXgvSbnq3wctTxtqN5F_HXnxuwPURoO3T50DRJhdocuRDJJetn8NbGf8BWdWP6Q</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Pekary, A. Eugene</creator><creator>Sattin, Albert</creator><creator>Lloyd, Robert L.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201507</creationdate><title>Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats</title><author>Pekary, A. Eugene ; Sattin, Albert ; Lloyd, Robert L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-94cdceba12e67649f7052f753134870ae6ea31f568ad7c24bafeb1a09d2b1b693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Anxiety</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Brain - physiopathology</topic><topic>Depression</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Depressive Disorder, Major - metabolism</topic><topic>Depressive Disorder, Major - physiopathology</topic><topic>Humans</topic><topic>Ketamine - administration &amp; dosage</topic><topic>Ketamine - metabolism</topic><topic>Limbic system</topic><topic>Male</topic><topic>N-Methylaspartate - antagonists &amp; inhibitors</topic><topic>N-Methylaspartate - metabolism</topic><topic>Neuroendocrine</topic><topic>Peptides - metabolism</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Suicide</topic><topic>Thyrotropin-Releasing Hormone - biosynthesis</topic><topic>Thyrotropin-Releasing Hormone - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pekary, A. Eugene</creatorcontrib><creatorcontrib>Sattin, Albert</creatorcontrib><creatorcontrib>Lloyd, Robert L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Peptides (New York, N.Y. : 1980)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pekary, A. Eugene</au><au>Sattin, Albert</au><au>Lloyd, Robert L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats</atitle><jtitle>Peptides (New York, N.Y. : 1980)</jtitle><addtitle>Peptides</addtitle><date>2015-07</date><risdate>2015</risdate><volume>69</volume><spage>66</spage><epage>76</epage><pages>66-76</pages><issn>0196-9781</issn><eissn>1873-5169</eissn><abstract>•TRH and TRH-like peptides increase throughout limbic system 1h after ketamine.•This increase may be due to increased ascorbate-dependent synthesis of TRH-like peptides.•Glu-TRH increased levels of TRH-like peptides via competitive inhibition of degrading enzymes.•Anxiolytic effects of ketamine may be mediated by TRH and/or TRH-like peptides. Major depression is the largest single healthcare burden with treatments of slow onset and often limited efficacy. Ketamine, a NMDA antagonist used extensively as a pediatric and veterinary anesthetic, has recently been shown to be a rapid acting antidepressant, making it a potential lifesaver for suicidal patients. Side effects and risk of abuse limit the chronic use of ketamine. More complete understanding of the neurobiochemical mechanisms of ketamine should lead to safer alternatives. Some of the physiological and pharmacological actions of ketamine are consistent with increased synthesis and release of TRH (pGlu-His-Pro-NH2), and TRH-like peptides (pGlu-X-Pro-NH2) where “X” can be any amino acid residue. Moreover, TRH-like peptides are themselves potential therapeutic agents for the treatment of major depression, anxiety, bipolar disorder, epilepsy, Alzheimer's and Parkinson's diseases. For these reasons, male Sprague–Dawley rats were anesthetized with 162mg/kg ip ketamine and then infused intranasally with 20μl of sterile saline containing either 0 or 5mg/ml Glu-TRH. One, 2 or 4h later, the brain levels of TRH and TRH-like peptides were measured in various brain regions and peripheral tissues. At 1h in brain following ketamine only, the levels of TRH and TRH-like peptides were significantly increased in 52 instances (due to increased biosynthesis and/or decreased release) or decreased in five instances. These changes, listed by brain region in order of decreasing number of significant increases (↑) and/or decreases (↓), were: hypothalamus (9↑); piriform cortex (8↑); entorhinal cortex (7↑); nucleus accumbens (7↑); posterior cingulate (5↑); striatum (4↑); frontal cortex (2↑,3↓); amygdala (3↑); medulla oblongata (1↑,2↓); cerebellum (2↑); hippocampus (2↑); anterior cingulate (2↑). The corresponding changes in peripheral tissues were: adrenals (8↑); epididymis (4↑); testis (1↑,3↓); pancreas (1↑); prostate (1↑). We conclude that TRH and TRH-like peptides may be downstream mediators of the rapid antidepressant actions of ketamine.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25882008</pmid><doi>10.1016/j.peptides.2015.04.003</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0196-9781
ispartof Peptides (New York, N.Y. : 1980), 2015-07, Vol.69, p.66-76
issn 0196-9781
1873-5169
language eng
recordid cdi_proquest_miscellaneous_1684432795
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Anxiety
Brain - drug effects
Brain - metabolism
Brain - physiopathology
Depression
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - metabolism
Depressive Disorder, Major - physiopathology
Humans
Ketamine - administration & dosage
Ketamine - metabolism
Limbic system
Male
N-Methylaspartate - antagonists & inhibitors
N-Methylaspartate - metabolism
Neuroendocrine
Peptides - metabolism
Rats
Rats, Sprague-Dawley
Suicide
Thyrotropin-Releasing Hormone - biosynthesis
Thyrotropin-Releasing Hormone - metabolism
title Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T23%3A44%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ketamine%20modulates%20TRH%20and%20TRH-like%20peptide%20turnover%20in%20brain%20and%20peripheral%20tissues%20of%20male%20rats&rft.jtitle=Peptides%20(New%20York,%20N.Y.%20:%201980)&rft.au=Pekary,%20A.%20Eugene&rft.date=2015-07&rft.volume=69&rft.spage=66&rft.epage=76&rft.pages=66-76&rft.issn=0196-9781&rft.eissn=1873-5169&rft_id=info:doi/10.1016/j.peptides.2015.04.003&rft_dat=%3Cproquest_cross%3E1684432795%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1684432795&rft_id=info:pmid/25882008&rft_els_id=S0196978115001084&rfr_iscdi=true